Youcare Pharmaceutical Gets China Clinical Trial Nod for Respiratory Syncytial Virus, Shingles Jabs
China's drug regulator approved the phase 1 clinical trial application for the YKYY025 injection of Youcare Pharmaceutical (SHA:688658) subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology and Hangzhou Tianlong Pharmaceutical.The vaccine is indicated for the prevention of lower respiratory tract diseases caused by respiratory syncytial virus, according to a Tuesday disclosure to the Shanghai Stock Exchange.The regulator also approved the subsidiaries' YKYY026 vaccine for herpes zoster or shingles, according to a separate filing.